Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: An opportunity at a low cost

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bartsch, Emily ^a   Park, Alison L ^b   Kingdom, John C ^c   Ray, Joel G ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; DOSE RESPONSE; DRUG COST; FEMALE; HUMAN; LOW DRUG DOSE; MINIMUM CONTROL EVENT RATE; MINIMUM EVENT RATE FOR TREATMENT; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREVENTIVE MEDICINE; RISK ASSESSMENT; STATISTICAL CONCEPTS; CONTROLLED STUDY; PRE-ECLAMPSIA; RANDOMIZED CONTROLLED TRIAL; RISK;

ASPIRIN; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK;

EID: 84961292013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116296     Document Type: Article

References (33)

1. National Collaborating Centre for Women's and Children's Health (UK) (2010) Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press. 1194 p. PMID: 22220321
2. Hutcheon J, Lisonkova S, Joseph K (2011) Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 25: 391-403. doi: 10.1016/j.bpobgyn.2011.01.006 PMID: 21333604
3. Caritis S, Sibai B, Hauth J, Lindheimer M, Klebanoff M, et al. (1998) Low-dose aspirin to prevent pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 338: 701-705. PMID: 9494145
4. Ananth C, Friedman A (2014) Ischemic placental disease and risks of perinatal mortality and morbidity and neurodevelopmental disorders. Semin Perinatol 38: 151-158. doi: 10.1053/j.semperi.2014.03.007 PMID: 24836827
5. Loverro G, Pansini V, Greco P, Vimercati A, Parisi A, et al. (2001) Indications and outcome for intensive care unit admission during puerperium. Arch Gynecol Obstet 265: 195-198. PMID: 11789744
6. Ray J, Urquia M, Berger H, Vermeulen M (2012) Maternal and neonatal separation and mortality associated with concurrent admissions to intensive care units. CMAJ 184: E956-962. doi: 10.1503/cmaj.121283 PMID: 23091180
7. Public Health Agency of Canada (2013) Perinatal Health Indicators for Canada 2013. Available: http://www.aphp.ca/pdf/CAC%20report%202013%20EN.pdf. Accessed 03 August 2014.
8. Basso O, Rasmussen S, Weinberg C, Wilcox A, Irgens L, et al. (2006) Trends in fetal and infant survival following preeclampsia. JAMA 296: 1357-1362. PMID: 16985227
9. Ananth C, Savitz D, Luther E, Bowes WJ (1997) Preeclampsia and preterm birth subtypes in Nova Scotia, 1986 to 1992. Am J Perinatol 14: 17-23. PMID: 9259891
10. Odegard R, Vatten L, Nilsen S, Salvesen K, Austgulen R (2000) Preeclampsia and fetal growth. Obstet Gynecol 96: 950-955. PMID: 11084184
11. Duley L, Henderson-Smart D, Meher S, King J (2007) Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2:CD004659. PMID: 17443552
12. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, et al. (2012) Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 31: 141-146. doi: 10.1159/000336662 PMID: 22441437
13. Roberge S, Nicolaides K, Demers S, Villa P, Bujold E (2013) Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 41: 491-499. doi: 10.1002/uog.12421 PMID: 23362106
14. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, et al. (2010) Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116: 402-414. doi: 10.1097/AOG.0b013e3181e9322a PMID: 20664402
15. Imperiale T, Petrulis A (1991) A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA 266: 260-264. PMID: 1829118
16. Chappell L, Seed P, Enye S, Briley A, Poston L, et al. (2010) Clinical and geographical variation in prophylactic and therapeutic treatments for pre-eclampsia in the UK. BJOG 117: 695-700. doi: 10.1111/j.1471-0528.2010.02507.x PMID: 20175876
17. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, et al. (2014) Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 348: g2301. doi: 10.1136/bmj.g2301 PMID: 24735917
18. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, et al. (2011) Clinical risk prediction for preeclampsia in nulliparous women: development of model in international prospective cohort. BMJ 342: d1875. doi: 10.1136/bmj.d1875 PMID: 21474517
19. Laupacis A, Sackett D, Roberts R (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733. PMID: 3374545
20. Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310: 452-454. PMID: 7873954
21. Sinclair J, Cook R, Guyatt G, Pauker S, Cook D (2001) When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 54: 253-262. PMID: 11223323
22. National Cholesterol Education Program (1994) Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 89: 1333-1445. PMID: 8124825
23. Laupacis A, Feeny D, Detsky A, Tugwell P (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146: 473-481. PMID: 1306034
24. Shimbo T, Nagata-Kobayashi S, Morimoto T, Fukui T (2002) Quick estimation of threshold "number needed to treat". J Clin Epidemiol 55: 531. PMID: 12007558
25. Earnshaw S, Scheiman J, Fendrick A, McDade C, Pignone M (2011) Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 171: 218-225. doi: 10.1001/archinternmed.2010.525 PMID: 21325111
26. Li R, Zhang P, Barker L, Hoerger T (2010) Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care 33: 1193-1199. doi: 10.2337/dc09-1888 PMID: 20332350
27. Xiong X, Mayes D, Demianczuk N, Olson D, Davidge S, et al. (1999) Impact of pregnancy-induced hypertension on fetal growth. Am J Obstet Gynecol 180: 207-213. PMID: 9914605
28. Walter S, Sinclair J (2009) Uncertainty in the minimum event risk to justify treatment was evaluated. J Clin Epidemiol 62: 816-824. doi: 10.1016/j.jclinepi.2008.09.017 PMID: 19216053
29. Schwartz LM, Woloshin S, Dvorin EL, Welch HG (2006) Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ 333: 1248. PMID: 17060338
30. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group (1994) CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 343: 619-629. PMID: 7906809
31. Schisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, et al. (2014) Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet 384: 29-36. doi: 10.1016/S0140-6736(14)60157-4 PMID: 24702835
32. Henderson JT, Whitlock EP, O'Conner E, Senger CA, Thompson JH, et al. (2014) Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the US Preventive Services Task Force. Agency for Healthcare Research and Quality (US) Report No.: 14-05207-EF-1.
33. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369: 1791-1798. PMID: 17512048